Dempster, David W <br/><br/>
Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.  [electronic resource] 

 -  Clinical therapeutics  Mar 2012 
 - 521-36 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1879-114X 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2012.02.002  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacokinetics<br/>Antibodies, Monoclonal, Humanized<br/>Bone Density--drug effects<br/>Bone Remodeling--drug effects<br/>Bone and Bones--drug effects<br/>Clinical Trials as Topic<br/>Denosumab<br/>Disease Models, Animal<br/>Drug Evaluation, Preclinical<br/>Estrogens--deficiency<br/>Female<br/>Humans<br/>Osteoporosis--drug therapy<br/>Osteoporosis, Postmenopausal--drug therapy<br/>RANK Ligand--antagonists & inhibitors<br/>Testosterone--deficiency<br/>Treatment Outcome